List view / Grid view
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
CNIC researchers have identified a mechanism in fat cells that helps them safely store excess fat, offering new insights for combating obesity and related metabolic diseases.
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
The agreement between Cartherics, The University of Sydney and The University of Queensland will further stem cell-derived heart muscle therapy for heart failure.
In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches.
In this Q&A, Associate Professor Dr Mete Civelek shares insights from the University of Virginia’s exciting recent study identifying several potential therapeutic targets for accelerating translational research in cardiovascular disease treatment, with a focus on proteins associated with the extracellular matrix (ECM) secretion by smooth muscle cells (SMCs).
Researchers have gained a deeper understanding of the neural biology of obesity, which could offer potential drug targets.
The first multi-chamber cardioids derived from hiPSCs have enabled scientists to investigate heart development and defects.
The University of California underwent a mouse study disclosing underlying sex differences in mice for obesity.
Fresh insights from University of Edinburgh into a protein that causes damage in kidneys and hearts could open up new treatment options for chronic kidney disease.
The new findings could pave the way to safer aspirin alternatives and might also have implications for improving cancer immunotherapies.
US researchers have discovered that cancer treatments or anthracycline drugs, cause cardiovascular disease by activating a key inflammatory signalling pathway.
Elevated lipoprotein(a), or Lp(a), is a major risk factor for cardiovascular disease that affects one in five people worldwide, but currently lacks approved therapies. Here, Dr Giles Campion, EVP, Head of R&D and Chief Medical Officer of Silence Therapeutics, describes the company’s approach to developing an investigational siRNA therapy designed…
Drug-initiated activity metabolomics screening discovers the metabolite myristoylglycine, that converts white fat cells to brown fat cells.
A recent pre-clinical study from Washington University School of Medicine showed that a new class of compounds can potentially improve multiple aspects of metabolic syndrome, including diabetes.
